Resilient Clinical Trial Infrastructure in Response to the COVID-19 Pandemic: Lessons Learned from the TOGETHER Randomized Platform Clinical Trial
Jamie I Forrest, Angeli Rawat, Felipe Duailibe, Christina M Guo, Sheila Sprague, Paula McKay, Gilmar Reis, Edward J Mills, Jamie I Forrest, Angeli Rawat, Felipe Duailibe, Christina M Guo, Sheila Sprague, Paula McKay, Gilmar Reis, Edward J Mills
Abstract
In response to the COVID-19 pandemic, clinical research groups across the world developed trial protocols to evaluate the safety and efficacy of treatments for COVID-19. Despite this initial enthusiasm, only a small portion of these protocols were implemented. Of those implemented, a fraction successfully recruited their target sample size to analyze and disseminate findings. More than a year and a half into the COVID-19 pandemic, only a few clinical trials evaluating treatments for COVID-19 have generated new evidence. Productive randomized platform clinical trials evaluating COVID-19 treatments may attribute their success to intentional investments in developing resilient clinical trial infrastructures. Health system resiliency discourse provides a conceptual framework for characterizing attributes for withstanding shocks. This framework may also be useful for contextualizing the attributes of productive clinical trials evaluating COVID-19 therapies. We characterize the successful attributes and lessons learned in developing the TOGETHER Trial infrastructure using a health system resiliency framework. This framework may be considered by clinical trialists aiming to build resilient trial infrastructures capable of responding rapidly and efficiently to global health threats.
Figures
References
- Thorlund K Dron L Park J Hsu G Forrest JI Mills EJ , 2020. A real-time dashboard of clinical trials for COVID-19. Lancet Digit Health 2: e286–e287.
- Pan H et al. 2021. Repurposed antiviral drugs for COVID-19: interim WHO Solidarity Trial results. N Engl J Med 384: 497–511.
- RECOVERY Collaborative Group , 2020. Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 396: 1345–1352.
- RECOVERY Collaborative Group , 2021. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 397: 1637–1645.
- RECOVERY Collaborative Group , 2021. Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 397: 605–612.
- Butler CC et al. 2021. Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet 397: 1063–1074.
- Butler CC et al. 2021. Doxycycline for community treatment of suspected COVID-19 in people at high risk of adverse outcomes in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet Respir Med 9: 1010–1020.
- Yu L-M et al. 2021. Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet 398: 843–855.
- Angus DC et al. 2020. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19. JAMA 324: 1317–1329.
- REMAP-CAP, ACTIV-4a, and ATTACC Investigators , 2021. Therapeutic anticoagulation with heparin in critically ill patients with COVID-19. N Engl J Med 385: 777–789.
- Reis G et al. 2021. Effect of early treatment with hydroxychloroquine or lopinavir and ritonavir on risk of hospitalization among patients with COVID-19: the TOGETHER randomized clinical trial. JAMA Netw Open 4: e216468: 1010–1020.
- Reis G et al. 2021. A multi-center, adaptive, randomized, platform trial to evaluate the effect of repurposed medicines in outpatients with early coronavirus disease 2019 (COVID-19) and high-risk for complications: the TOGETHER master trial protocol. Gates Open Res 5: 117.
- Duley L et al. 2008. Specific barriers to the conduct of randomized trials. Clin Trials 5: 40–48.
- Kruk ME Myers M Varpilah ST Dahn BT , 2015. What is a resilient health system? Lessons from Ebola. Lancet 385: 1910–1912.
- Lee Z Rayner CR Forrest JI Nachega JB Senchaudhuri E Mills EJ , 2021. The rise and fall of hydroxychloroquine for the treatment and prevention of COVID-19. Am J Trop Med Hyg 104: 35–38.
- Woodcock J LaVange LM , 2017. Master protocols to study multiple therapies, multiple diseases, or both. N Engl J Med 377: 62–70.
- Forrest JI Rayner CR Park JJH Mills EJ , 2020. Early treatment of COVID-19 disease: a missed opportunity. Infect Dis Ther 9: 715–720.
Source: PubMed